COVID-19: Vaccine production consignment from Kaneka and Inovio Pharmaceuticals: DNA medicines to treat
[December 3, Reuters]
Inovio Pharmaceuticals:
On December 3, Inovio announced that it had agreed to outsource the production of the new coronavirus vaccine to Kaneka.
The agreement will be signed between Inovio and Kaneka Eurogentech.
The conditions have not been announced.
Inovio has already agreed with Thermo Fisher Scientific to outsource vaccine production.
Inovio Corona Vaccine:
Inovio’s corona vaccine is currently in some phase 3 clinical trials pending.
The FDA needs more information on the equipment used during vaccination.
Reuters
https://jp.reuters.com/article/health-coronavirus-inovio-pharma-idJPKBN28D2BN
Inovio Pharmaceuticals, Inc. – INOVIO Expands Global Manufacturing Consortium For Its COVID-19 Vaccine Candidate INO-4800 With Addition of Kaneka Eurogentec S.A.
PLYMOUTH MEETING, Pa.,
Dec. 3, 2020 /PRNewswire/
INOVIO (NASDAQ:INO), a biotechnology company
focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer,
today announced the execution of an agreement with Kaneka Eurogentec S.A., an affiliate of Kaneka Corporation,
for Eurogentec to manufacture INOVIO’s COVID-19 vaccine candidate INO-4800 at their industry-leading GMP plasmid production scales.
Terms of the agreement were not disclosed.
Kaneka Eurogentec
joins existing partners
Thermo Fisher Scientific,
Richter-Helm BioLogics and
Ology Biosciences
in INOVIO’s global manufacturing consortium.
Each contract development and manufacturing organization that has been selected to join the consortium is compliant with commercial GMP standards and capable of supporting INOVIO’s future large-scale global manufacturing needs across its portfolio of DNA medicines and vaccines